Prediction: This Pharma Stock Will Be the Best Performer the Rest of 2024
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Vir Biotechnology.
Headquartered in The Mediaworks, London Fiscal year ends December NASDAQ: AUTL autolus.com
Autolus Therapeutics is a commercial-stage biopharmaceutical company that develops, manufactures and delivers programmed T cell therapies for cancer and autoimmune disease. It uses a suite of proprietary, modular T cell programming technologies.
Its marketed product is AUCATZYL (obecabtagene autoleucel; obe-cel), a CD19-directed autologous CAR T cell therapy. AUCATZYL is engineered with a fast target-binding off-rate to limit excessive T cell activation. It was approved by the FDA in November 2024 for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL), and received conditional marketing authorization from the UK MHRA and the EU EMA in 2025. The product is sold through 90 U.S. authorized treatment centers and in the UK.
Autolus is pursuing a 'pipeline-in-a-product' strategy to expand obe-cel into new indications:
- Pediatric r/r B-ALL (CATULUS Phase 1/2)
- Systemic lupus erythematosus (CARLYSLE Phase 1)
- Lupus nephritis (pivotal LUMINA Phase 2; obe-cel holds FDA RMAT designation for SLE and lupus nephritis)
- Progressive multiple sclerosis (BOBCAT Phase 1)
The company is also developing AUTO8 for light-chain amyloidosis (ALARIC Phase 1). Operations are funded by product revenue, existing cash and a senior secured credit facility with Perceptive Advisors. Updated
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Vir Biotechnology.
Monday’s top analyst upgrades and downgrades included Chipotle Mexican Grill, CRISPR, Hess Midstream, iMedia Brands, Kinder Morgan, Wendy’s and more.
Autolus Therapeutics is a commercial-stage biopharmaceutical company that develops, manufactures and delivers programmed T cell therapies for cancer and autoimmune disease. It uses a suite of proprietary, modular T cell programming technologies.
The Wall Street consensus 12-month price target for AUTL is $8.36.